Condition
Heart Failure
Locations
India, Poland, South Korea, Spain, United States
Start date
27/06/2025
Identifiers
Trial ID
NN6706-8212,
NCT number NCT06979362,
Eudract number Not Available
NCT number NCT06979362,
Eudract number Not Available
Summary
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
Trial Overview:
Treatment
DRUG: CDR132L
DRUG: Placebo
Study type
INTERVENTIONAL
Trial duration
Jun 27 2025 - Jan 23 2028
Participants
200
Phase
II
Are you eligible?
Gender
Male and female
Age
40 to 84 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.